EA201690425A1 - Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии - Google Patents
Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазииInfo
- Publication number
- EA201690425A1 EA201690425A1 EA201690425A EA201690425A EA201690425A1 EA 201690425 A1 EA201690425 A1 EA 201690425A1 EA 201690425 A EA201690425 A EA 201690425A EA 201690425 A EA201690425 A EA 201690425A EA 201690425 A1 EA201690425 A1 EA 201690425A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- newcastle disease
- neoplasia
- treatment
- application
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title abstract 2
- 208000010359 Newcastle Disease Diseases 0.000 title 1
- 230000002238 attenuated effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009826 neoplastic cell growth Effects 0.000 title 1
- 241000711404 Avian avulavirus 1 Species 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 1
- 230000000174 oncolytic effect Effects 0.000 abstract 1
- 244000144977 poultry Species 0.000 abstract 1
- 230000007026 protein scission Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
В настоящем изобретении раскрыты способы индуцирования регрессии опухолей у субъектов-людей, при этом в способах используется модифицированный мезогенный штамм вируса ньюкаслской болезни (NDV) с модифицированным сайтом расщепления F-белка, который является непатогенным для домашней птицы (лентогенный), но проявляет онколитические свойства. Раскрытые способы обеспечивают безопасное, эффективное и надежное средство для индуцирования регрессии опухоли у индивида, нуждающегося в этом. Эти способы преодолевают недостатки применения патогенных штаммов вирусов для терапии человека.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361873039P | 2013-09-03 | 2013-09-03 | |
| PCT/EP2014/068619 WO2015032755A1 (en) | 2013-09-03 | 2014-09-02 | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201690425A1 true EA201690425A1 (ru) | 2016-08-31 |
| EA039404B1 EA039404B1 (ru) | 2022-01-24 |
Family
ID=51492938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690425A EA039404B1 (ru) | 2013-09-03 | 2014-09-02 | Аттенуированный вирус ньюкаслской болезни (ndv) штамма 73т для лечения неоплазии, способ селективного цитолиза опухолевых клеток и способ индуцирования регресса опухоли с его использованием |
| EA202191926A EA202191926A3 (ru) | 2013-09-03 | 2014-09-02 | Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191926A EA202191926A3 (ru) | 2013-09-03 | 2014-09-02 | Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10519426B2 (ru) |
| EP (3) | EP3508209B1 (ru) |
| JP (2) | JP6557234B2 (ru) |
| KR (2) | KR102285894B1 (ru) |
| CN (2) | CN106163532B (ru) |
| AU (2) | AU2014317215C1 (ru) |
| CA (1) | CA2922071C (ru) |
| CY (1) | CY1121993T1 (ru) |
| DK (2) | DK3508209T3 (ru) |
| EA (2) | EA039404B1 (ru) |
| ES (2) | ES2914577T3 (ru) |
| HK (2) | HK1225643B (ru) |
| HR (2) | HRP20220653T1 (ru) |
| HU (1) | HUE042382T2 (ru) |
| LT (2) | LT3041490T (ru) |
| ME (1) | ME03345B (ru) |
| MX (2) | MX367768B (ru) |
| PL (2) | PL3041490T3 (ru) |
| PT (2) | PT3041490T (ru) |
| RS (2) | RS58332B1 (ru) |
| SI (2) | SI3508209T1 (ru) |
| TR (1) | TR201902073T4 (ru) |
| TW (1) | TWI653334B (ru) |
| WO (1) | WO2015032755A1 (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA016217B1 (ru) | 2005-12-02 | 2012-03-30 | Маунт Синай Скул Оф Медсин | Химерные вирусы, представляющие неприродные поверхностные белки, и их применение |
| EP2393921B1 (en) | 2009-02-05 | 2015-07-15 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses and uses thereof |
| JP6596411B2 (ja) | 2013-03-14 | 2019-10-23 | アイカーン スクール オブ メディシン アット マウント サイナイ | ニューカッスル病ウイルス及びその使用 |
| RS58332B1 (sr) * | 2013-09-03 | 2019-03-29 | Medimmune Ltd | Sastavi koji sadrže oslabljeni virus njukastl bolesti i postupci upotrebe za tretiranje neoplazije |
| KR102407019B1 (ko) | 2014-02-27 | 2022-06-08 | 머크 샤프 앤드 돔 코포레이션 | 암의 치료를 위한 결합 방법 |
| US10563178B2 (en) * | 2015-04-28 | 2020-02-18 | University Of Georgia Research Foundation, Inc. | PIV5-based amplifying virus-like particles |
| EP3805376A1 (en) | 2016-01-08 | 2021-04-14 | Replimune Limited | Engineered virus |
| EP3246410A1 (en) * | 2016-05-19 | 2017-11-22 | Klinikum rechts der Isar der Technischen Universität München | Vsv/ndv hybrid viruses for oncolytic therapy of cancer |
| KR101964610B1 (ko) * | 2017-03-13 | 2019-04-03 | 대한민국 | 신규한 종양용해성 바이러스 및 이의 용도 |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CN107254450A (zh) * | 2017-07-20 | 2017-10-17 | 扬州大学 | 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法 |
| CN108486279A (zh) * | 2017-09-21 | 2018-09-04 | 山东省农业科学院家禽研究所 | 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法 |
| EP3552608A1 (en) * | 2018-04-09 | 2019-10-16 | Rapo Yerape B.H. Ltd | Increased activity of oncoloytic newcastle disease virus |
| US20200297787A1 (en) * | 2018-07-13 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Apmv and uses thereof for the treatment of cancer |
| CN110859968A (zh) * | 2019-11-21 | 2020-03-06 | 四川安可康生物医药有限公司 | 激活对肿瘤的系统免疫反应的基因生物药物 |
| CN115197949A (zh) * | 2021-04-13 | 2022-10-18 | 江苏康缘瑞翱生物医药科技有限公司 | 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7724558B1 (en) * | 1999-03-19 | 2010-05-25 | Nec Corporation | Magnetic signal transmission line |
| AU7607900A (en) * | 1999-09-22 | 2001-04-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| KR100801180B1 (ko) * | 2006-09-26 | 2008-02-05 | 주식회사 고려비엔피 | 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신 |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| US20090208495A1 (en) * | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
| EP2393921B1 (en) * | 2009-02-05 | 2015-07-15 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses and uses thereof |
| JP6596411B2 (ja) * | 2013-03-14 | 2019-10-23 | アイカーン スクール オブ メディシン アット マウント サイナイ | ニューカッスル病ウイルス及びその使用 |
| RS58332B1 (sr) * | 2013-09-03 | 2019-03-29 | Medimmune Ltd | Sastavi koji sadrže oslabljeni virus njukastl bolesti i postupci upotrebe za tretiranje neoplazije |
| CN109099045A (zh) * | 2018-10-30 | 2018-12-28 | 浙江斯泰新材料科技股份有限公司 | 防松锁固型螺钉 |
-
2014
- 2014-09-02 RS RS20190176A patent/RS58332B1/sr unknown
- 2014-09-02 AU AU2014317215A patent/AU2014317215C1/en active Active
- 2014-09-02 PT PT14761317T patent/PT3041490T/pt unknown
- 2014-09-02 SI SI201431957T patent/SI3508209T1/sl unknown
- 2014-09-02 TR TR2019/02073T patent/TR201902073T4/tr unknown
- 2014-09-02 PL PL14761317T patent/PL3041490T3/pl unknown
- 2014-09-02 EP EP18188565.8A patent/EP3508209B1/en active Active
- 2014-09-02 WO PCT/EP2014/068619 patent/WO2015032755A1/en active Application Filing
- 2014-09-02 KR KR1020167008307A patent/KR102285894B1/ko active IP Right Grant
- 2014-09-02 DK DK18188565.8T patent/DK3508209T3/da active
- 2014-09-02 SI SI201431082T patent/SI3041490T1/sl unknown
- 2014-09-02 ES ES18188565T patent/ES2914577T3/es active Active
- 2014-09-02 RS RS20220481A patent/RS63291B1/sr unknown
- 2014-09-02 LT LTEP14761317.8T patent/LT3041490T/lt unknown
- 2014-09-02 ES ES14761317T patent/ES2708755T3/es active Active
- 2014-09-02 EA EA201690425A patent/EA039404B1/ru unknown
- 2014-09-02 JP JP2016537333A patent/JP6557234B2/ja active Active
- 2014-09-02 HU HUE14761317A patent/HUE042382T2/hu unknown
- 2014-09-02 PT PT181885658T patent/PT3508209T/pt unknown
- 2014-09-02 EA EA202191926A patent/EA202191926A3/ru unknown
- 2014-09-02 ME MEP-2019-40A patent/ME03345B/me unknown
- 2014-09-02 CN CN201480048630.4A patent/CN106163532B/zh active Active
- 2014-09-02 EP EP22160157.8A patent/EP4101457A1/en not_active Withdrawn
- 2014-09-02 HR HRP20220653TT patent/HRP20220653T1/hr unknown
- 2014-09-02 CA CA2922071A patent/CA2922071C/en active Active
- 2014-09-02 PL PL18188565T patent/PL3508209T3/pl unknown
- 2014-09-02 MX MX2016002771A patent/MX367768B/es active IP Right Grant
- 2014-09-02 EP EP14761317.8A patent/EP3041490B1/en active Active
- 2014-09-02 DK DK14761317.8T patent/DK3041490T3/en active
- 2014-09-02 LT LTEP18188565.8T patent/LT3508209T/lt unknown
- 2014-09-02 KR KR1020217012332A patent/KR102310692B1/ko active IP Right Grant
- 2014-09-02 US US14/916,102 patent/US10519426B2/en active Active
- 2014-09-02 CN CN202010064863.0A patent/CN111944767A/zh active Pending
- 2014-09-03 TW TW103130466A patent/TWI653334B/zh active
-
2016
- 2016-03-02 MX MX2019010364A patent/MX2019010364A/es unknown
- 2016-12-12 HK HK16114099A patent/HK1225643B/zh unknown
-
2017
- 2017-05-22 HK HK17105137.4A patent/HK1231393A1/zh unknown
-
2019
- 2019-02-07 HR HRP20190250TT patent/HRP20190250T1/hr unknown
- 2019-02-08 CY CY20191100170T patent/CY1121993T1/el unknown
- 2019-06-24 AU AU2019204419A patent/AU2019204419B2/en active Active
- 2019-07-11 JP JP2019129161A patent/JP6862500B2/ja active Active
- 2019-11-14 US US16/684,241 patent/US11471499B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690425A1 (ru) | Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии | |
| CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
| EA201301173A1 (ru) | Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования | |
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| AR091316A1 (es) | Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos | |
| EA201790413A1 (ru) | Антитела против tigit | |
| EA201790377A1 (ru) | Антитела к глюкагону и их применения | |
| NI201500131A (es) | Virus de la enfermedad de newcastle y usos de los mismos | |
| CL2015002570A1 (es) | Anticuerpos humanos de la proteína f del virus respiratorio sincitial y métodos de uso de estos | |
| EA201692098A1 (ru) | Биокерамические композиции и их применение для биомодулирования | |
| BR112017001310A2 (pt) | coronavírus | |
| CU23938B1 (es) | Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2 | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| CO2017012454A2 (es) | Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia | |
| MX2017004897A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
| CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
| EA201691314A1 (ru) | Терапевтические способы и композиции | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| MX2017007187A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
| EA201691443A1 (ru) | Накожное восстановление иммунобаланса | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| BR112018015893A2 (pt) | vacinas de câncer e métodos de tratamento usando as mesmas | |
| BR112016006210A2 (pt) | terapia e vacina contra gripe | |
| BR112017025533A2 (pt) | método para tratar câncer em um paciente humano |